<DOC>
	<DOC>NCT00410930</DOC>
	<brief_summary>To compare versus placebo the efficacy and safety of recombinant Bet v1, natural purified Bet v1 and birch pollen licenced extract used for subcutaneous immunotherapy.</brief_summary>
	<brief_title>Efficacy and Safety of Subcutaneous Immunotherapy in Birch Pollen Allergic Patients</brief_title>
	<detailed_description />
	<criteria>Patients aged 1850 with seasonal rhinoconjunctivitis for at least 2 years, and/or mild asthma range 1 and 2 GINA. Positive history of birch pollen allergy (clinical history, positive skin prick test, birch specific IgE, presence of birch pollen) Compliant patients Written consent. Perennial rhinoconjunctivitis and/or asthma due to cosensitization with: animal danders, mites, alternaria cladosporium Uncontrolled seasonal asthma : severe asthma permanent or not range 3 and 4 of GINA. Patients treated with betablockers or under continuous oral corticosteroids. Pregnant women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Immunotherapy, major allergen, birch</keyword>
</DOC>